Patent intelligence · WO
WO 2023077094
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
Patent details — WO 2023077094
- Jurisdiction
- WO
- Status
- granted
- Grant date
- May 4, 2023
- Expiration
- Apr 29, 2043
- Applicant
- ABBVIE INC [US]
- CPC classes
- A61K 31/ 495 A I, A61K/31495, A61K/31496, A61K/4506
Quick answer
WO 2023077094 (TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR) is held by ABBVIE INC [US]. Status: granted. Granted May 4, 2023. Expires Apr 29, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 495 A I, A61K/31495, A61K/31496, A61K/4506, A61P 25/ 24 A I, A61P/2524
More from ABBVIE INC [US]
Related pharmaceutical patents in our USPTO index.
-
US 12383545
TREATMENT OF MIGRAINE
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
WO 2024081718
ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE
granted -
CA 3244873
TRAITEMENT PRÉVENTIF DE LA MIGRAINE
granted -
US 2023130736
METHODS OF TREATING MIGRAINE
granted -
US 2022380379
PHARMACEUTICAL COMPOUNDS
granted
Frequently asked questions
What is US patent 2023077094?
WO 2023077094 (TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR) is held by ABBVIE INC [US]. Status: granted. Granted May 4, 2023. Expires Apr 29, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2023077094?
ABBVIE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2023077094 expire?
Our index shows an expiration date of Apr 29, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.